ELSEVIER SCIENTIFIC PUBLISHERS IRELAND

Cancer Letters 75 (1993) 207–208

CANCER LETTERS

Subject index

Volume 75

Activated lymphocyte, progesterone, interleukin 2, 157
Apoptosis, monoclonal antibody, leukemia cells, metabolism, microcalorimetry, 103
Aromatase, breast cancer, tobacco alkaloid, inhibitor, estrogen biosynthesis, 175
Azoxymethane, wheat bran fiber, psyllium fiber, 53

Bladder cancer, schistosomiasis, hycanthone, metrifonate, oxaminiquine, DNA methylation damage, DNA repair, 167
Bladder carcinoma, cytokeratin, differential expression, 87
Breast cancer, aromatase, tobacco alkaloid, inhibitor, estrogen biosynthesis, 175
Breast cancer, fatty acids, invasion, 137
Breast cancer, HER-2/*neu*, p185, steroid receptors, cathepsin D, 195
Breast carcinoma, FSH, fibrocystic diseases, 1

c-*myc*, rat colon carcinogenesis, cell proliferation, magnesium hydroxide, methylazoxymethanol acetate, 73
C3 activation products, ricin A chain, ricin
B chain, terminal SC56-9 complement complex, 59
cadmium, lung, cancer, metallothionein, copper, 121
Cancer, HT-29-D4 cells, suramin, polarity, lysosomal disorder, quantitative autoradiography, 151
Cancer, lung, metallothionein, copper, cadmium, 121
Capsaicin, cytochrome P450, metabolism, NNK, 45
Carcinogenesis, inositol hexaphosphate, Sprague–Dawley rats, pilot study, 95
Carcinogenic potency, rodents, humans, dose level limit, 183
Cathepsin D, breast cancer, HER-2/*neu*, p185, steroid receptors, 195
Cell proliferation, c-*myc*, rat colon carcinogenesis, magnesium hydroxide, methylazoxymethanol acetate, 73
Cisplatin, small cell lung cancer, drug resistance, glutathione, glutathione *S*-transferase, 111
Combination therapy, tumor-induced angiogenesis, retinoids, vitamin D_3, 35
Copper, lung, cancer, metallothionein, cadmium, 121
Cytochrome P450, capsaicin, metabolism, NNK, 45
Cytokeratin, bladder carcinoma, differential expression, 87

Differential expression, bladder carcinoma, cytokeratin, 87
Differentiation marker, HER-2/*neu*, esophageal adenocarcinoma, 41
DNA 5-methylcytosine, mouse liver tumor, *Ha-ras*, methylation, oncogene, 129
DNA alkyltransferase, estrous cycle, O^6-methylguanine-DNA-methyltransferase, 11
DNA methylation damage, schistosomiasis, hycanthone, metrifonate, oxaminiquine, bladder cancer, DNA repair, 167
DNA repair, schistosomiasis, hycanthone, metrifonate, oxaminiquine, bladder cancer, DNA methylation damage, 167
Dominant negative mutation, *ras* oncogene, tumor suppression, 19
Dose level limit, carcinogenic potency, rodents, humans, 183
Drug resistance, cisplatin, small cell lung cancer, glutathione, glutathione *S*-transferase, 111

Esophageal adenocarcinoma, HER-2/*neu*, differentiation marker, 41
Estrogen biosynthesis, aromatase, breast cancer, tobacco alkaloid, inhibitor, 175
Estrous cycle, O^6-methylguanine-DNA-methyltransferase, DNA alkyltransferase, 11

Fatty acids, breast cancer, invasion, 137
Fibrocystic diseases, FSH, breast carcinoma, 1 5-Fluorouracil, renal cell cancer, lymphokine-activated killer cell, 27
FSH, breast carcinoma, fibrocystic diseases, 1

Glutathione, cisplatin, small cell lung cancer, drug resistance, glutathione *S*-transferase, 111
Glutathione *S*-transferase, cisplatin, small cell lung cancer, drug resistance, glutathione, 111

Ha-ras, mouse liver tumor, methylation, DNA 5-methylcytosine, oncogene, 129
Hematoporphyrins, photodynamic therapy, intravesical instillation, 65
HER-2/*neu*, differentiation marker, esophageal adenocarcinoma, 41

HER-2/*neu*, breast cancer, p185, steroid receptors, cathepsin D, 195
HT-29-D4 cells, cancer, suramin, polarity, lysosomal disoder, quantitative autoradiography, 151
Human colorectal tumor, α2,6-sialyltransferase, metastasis, serum determinations, tumor monitoring, 143
Humans, carcinogenic potency, rodents, dose level limit, 183
Hycanthone, schistosomiasis, metrifonate, oxaminiquine, bladder cancer, DNA methylation damage, DNA repair, 167

Inhibitor, aromatase, breast cancer, tobacco alkaloid, estrogen biosynthesis, 175
Inositol hexaphosphate, carcinogenesis, Sprague–Dawley rats, pilot study, 95
Interleukin 2, progesterone, activated lymphocyte, 157
Intravesical instillation, photodynamic therapy, hematoporphyrins, 65
Invasion, breast cancer, fatty acids, 137

Leukemia cells, monoclonal antibody, apoptosis, metabolism, microcalorimetry, 103
Lung, cancer, metallothionein, copper, cadmium, 121
Lung cancer, vasopressin, oxytocin, neurophysin, 79
Lymphokine-activated killer cell, 5-fluorouracil, renal cell cancer, 27
Lysosomal disorder, HT-29-D4 cells, cancer, suramin, polarity, quantitative autoradiography, 151

Magnesium hydroxide, c-*myc*, rat colon carcinogenesis, cell proliferation, methylazoxymethanol acetate, 73
Metabolism, capsaicin, cytochrome P450, NNK, 45
Metabolism, monoclonal antibody, apoptosis, leukemia cells, microcalorimetry, 103
Metallotionein, lung, cancer, copper, cadmium, 121
Metastasis, α2,6-sialyltransferase, human colorectal tumor, serum determinations, tumor monitoring, 143
Methylation, mouse liver tumor, *Ha-ras*, DNA 5-methylcytosine, oncogene, 129
Methylazoxymethanol acetate, c-*myc*, rat colon carcinogenesis, cell proliferation, magnesium hydroxide, 73
Metrifonate, schistosomiasis, hycanthone, oxaminiquine, bladder cancer, DNA methylation damage, DNA repair, 167
Microcalorimetry, monoclonal antibody, apoptosis, leukemia cells, metabolism, 103
Monoclonal antibody, apoptosis, leukemia cells, metabolism, microcalorimetry, 103
Mouse liver tumor, *Ha-ras*, methylation, DNA 5-methylcytosine, oncogene, 129

Neurophysin, vasopressin, oxytocin, lung cancer, 79
NNK, capsaicin, cytochrome P450, metabolism, 45

O^6-methylguanine-DNA-methyltransferase, estrous cycle, DNA alkyltransferase, 11
Oncogene, mouse liver tumor, *Ha-ras*, methylation, DNA 5-methylcytosine, 129
Oxaminiquine, schistosomiasis, hycanthone, metrifonate, bladder cancer, DNA methylation damage, DNA repair, 167
Oxytocin, vasopressin, neurophysin, lung cancer, 79

p185, breast cancer, HER-2/*neu*, steroid receptors, cathepsin D, 195

Photodynamic therapy, hematoporphyrins, intravesical instillation, 65
Pilot study, carcinogenesis, inositol hexaphosphate, Sprague–Dawley rats, 95
Polarity, HT-29-D4 cells, cancer, suramin, lysosomal disorder, quantitative autoradiography, 151
Progesterone, interleukin 2, activated lymphocyte, 157
Psyllium fiber, azoxymethane, wheat bran fiber, 53

Quantitative autoradiography, HT-29-D4 cells, cancer, suramin, polarity, lysosomal disorder, 151

ras oncogene, dominant negative mutation, tumor suppression, 19
Rat colon carcinogenesis, c-*myc*, cell proliferation, magnesium hydroxide, methylazoxymethanol acetate, 73
Renal cell cancer, 5-fluorouracil, lymphokine-activated killer cell, 27
Retinoids, tumor-induced angiogenesis, vitamin D_3, combination therapy, 35
Ricin A chain, ricin B chain, C3 activation products, terminal SC56-9 complement complex, 59
Ricin B chain, ricin A chain, C3 activation products, terminal SC56-9 complement complex, 59
Rodents, carcinogenic potency, humans, dose level limit, 183

Schistosomiasis, hycanthone, metrifonate, oxaminiquine, bladder cancer, DNA methylation damage, DNA repair, 167
Serum determinations, α2,6-sialyltransferase, human colorectal tumor, metastasis, tumor monitoring, 143
α2,6-sialyltransferase, human colorectal tumor, metastasis, serum determinations, tumor monitoring, 143
Small cell lung cancer, cisplatin, drug resistance, glutathione, glutathione *S*-transferase, 111
Sprague–Dawley rats, carcinogenesis, inositol hexaphosphate, pilot study, 95
Steroid receptors, breast cancer, HER-2/*neu*, p185, cathepsin D, 195
Suramin, HT-29-D4 cells, cancer, polarity, lysosomal disorder, quantitative autoradiography, 151

Terminal SC56-9 complement complex, ricin A chain, ricin B chain, C3 activation products, 59
Tobacco alkaloid, aromatase, breast cancer, inhibitor, estrogen biosynthesis, 175
Tumor monitoring, α2,6-sialyltransferase, human colorectal tumor, metastasis, serum determinations, 143
Tumor suppression, dominant negative mutation, *ras* oncogene, 19
Tumor-induced angiogenesis, retinoids, vitamin D_3, combination therapy, 35
Vasopressin, oxytocin, neurophysin, lung cancer, 79
Vitamin D_3, tumor-induced angiogenesis, retinoids, combination therapy, 35

Wheat bran fiber, azoxymethane, psyllium fiber, 53

ELSEVIER SCIENTIFIC PUBLISHERS IRELAND

Cancer Letters 75 (1993) 209–210

CANCER LETTERS

Author index

Volume 75

Alabaster, O. 53
Anderson, C.H. 11
Awasthi, S. 111
Awney, H.H. 167
Axelsson, B. 65

Badawi, A.F. 167
Baghdiguian, S. 151
Bajpai, K.K. 111
Baker, V. 195
Bansal, M. 95
Barker, S. 195
Beattie, C.W. 11
Bollag, W. 35
Borrebaeck, C.A.K. 103
Boudier, J.-A. 151
Boudier, J.-L. 151

Chang, B.-D. 11
Chinoy, R.F. 1
Ciardo, V. 195
Connolly, J.M. 137
Counts, J.L. 129

Davies, T.S. 183

Erner, S. 41

Fantini, J. 151
Frenkel, E.P. 111
Friedmann, A.S. 79
Frost, A. 53

Garde, S.V. 1
Garred, P. 59
Geßner, P. 143
Goldberg, M. 41
Goodman, J.I. 129

Hamilton, S.M. 45
Hart, B.A. 121
Hellsten, S. 65
Hetland, G. 59
Hussain, R.A. 11
Hwang, Y.-W. 19

Imai, T. 27

Jablonska, S. 35
Joseph, R. 1

Kadohama, N. 175
Kameyama, S. 87
Katagiri, A. 27
Kawamata, H. 87
Keller, S.M. 41
Kemmner, W. 143
Kimoto, Y. 157
Kimura, M. 27
Kuzumaki, N. 19

Leo, G. 195
Löfgren, L. 65
Lönnbro, P. 103

Majewski, S. 35
Marczak, M. 35
Marsigliante, S. 195
Memoli, V.A. 79
Miller, C.H. 45
Moan, J. 65
Mollnes, T.E. 59
Monro, A. 183
Mori, H. 73
Mostafa, M.H. 167
Mottaghi, A. 195
Muscella, A. 195

Nan, L. 87
North, W.G. 79

Ogiso, Y. 19
Osawa, Y. 175
Oyasu, R. 87

Panchal, C.J. 1
Peng, Q. 65

Quentmaier, A. 143

Riedl, S. 143
Rose, D.P. 137

Saitoh, K. 27
Sakamoto, K. 95
Sato, S. 27
Sauter, E.R. 41
Schön, A. 103
Shamsuddin, A.M. 95
Sharma, R. 111
Sheth, A.R. 1
Sheth, N.A. 1
Shih, T.Y. 19
Shintani, K. 175
Shivapurkar, N. 53
Singhal, S.S. 111
Srivastava, S.K. 111
Storelli, C. 195
Szmurlo, A. 35

Taguchi, T. 157
Tan, X. 87
Tanaka, T. 73
Tang, Z.C. 53
Teel, R.W. 45
Tomita, Y. 27
Tong, F.-Z. 157
Vacek, P.M. 121
Vinson, G.P. 195
Voss, G.W. 121
Vucenik, I. 95

Wallén-Öhman, M. 103
Wang, A. 73
Windahl, T. 65

Yoshimi, N. 73

Zhang, Z. 45